650628-72-1

Usage

Uses

Used in Pharmaceutical Industry:
4-(PYRROLIDIN-1-YLMETHYL)BENZALDEHYDE 97 is used as a key intermediate in the synthesis and production of various pharmaceuticals and organic compounds. Its unique chemical structure and reactivity make it a valuable component in the development of new drugs and medical treatments.
Used in Fragrance and Flavor Industry:
4-(PYRROLIDIN-1-YLMETHYL)BENZALDEHYDE 97 is used as a raw material for creating aromatic compounds, contributing to the development of fragrances and flavors. Its aromatic and aldehyde properties make it an essential ingredient in these applications.
Used in Research and Development:
4-(PYRROLIDIN-1-YLMETHYL)BENZALDEHYDE 97 is utilized in the research and development of new drugs and medical treatments due to its unique chemical structure and reactivity. It plays a crucial role in advancing scientific knowledge and innovation in the pharmaceutical and chemical industries.

InChI:InChI=1/C12H15NO/c14-10-12-5-3-11(4-6-12)9-13-7-1-2-8-13/h3-6,10H,1-2,7-9H2

Upstream product

• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 123-75-1 pyrrolidine 
• 103781-93-7 4-(dimethoxymethyl)benzenecarbaldehyde 
• 51359-78-5 4-(bromomethyl)benzaldehyde 
• 17201-43-3 4-cyanobenzyl bromide 
• 81172-89-6 terephthalaldehyde mono(diethylacetal) 
• 623-27-8 terephthalaldehyde, 
• 105-07-7 4-cyanobenzaldehyde 
• 78064-96-7 4-(pyrrolidin-1-ylmethyl)benzonitrile 
• 160598-45-8 4-Pyrrolidin-1-ylmethyl-benzoic acid methyl ester 
• 91271-60-2 4-(tetrahydro-1H-1-pyrrolylmethyl)phenylmethanol 

Downstream Products

• 1119280-76-0 (E)-5,6-dimethoxy-2-{4-[(pyrrolidin-1-yl)methyl]-benzylidene}-2,3-dihydroinden-1-one 
• 1192281-23-4 (E)-1-(2-hydroxy-4,5-dimethoxyphenyl)-3-[4-(pyrrolidin-1-ylmethyl)-phenyl]-prop-2-en-1-one 
• 1246935-98-7 6-(4-pyrrolidin-1-ylmethyl-phenyl)-fulvene 
• 1228587-66-3 [(6-amino-2-butoxy-5-nitro-pyrimidin-4-yl)-(4-pyrrolidin-1-ylmethyl-benzyl)amino]acetic acid ethyl ester 
• 1228585-41-8 4-amino-2-n-butoxy-8-[4’-(pyrrolidin-1“-ylmethyl)-benzyl]-5,6,7,8-tetrahydropteridin-6-one 

Relevant academic research and scientific papers

Development of inhibitors against mycobacterium abscessus tRNA (m1G37) Methyltransferase (TrmD) Using Fragment-Based Approaches

Mycobacterium abscessus (Mab) is a rapidly growing species of multidrug-resistant nontuberculous mycobacteria that has emerged as a growing threat to individuals with cystic fibrosis and other pre-existing chronic lung diseases. Mab pulmonary infections are difficult, or sometimes impossible, to treat and result in accelerated lung function decline and premature death. There is therefore an urgent need to develop novel antibiotics with improved efficacy. tRNA (m1G37) methyltransferase (TrmD) is a promising target for novel antibiotics. It is essential in Mab and other mycobacteria, improving reading frame maintenance on the ribosome to prevent frameshift errors. In this work, a fragment-based approach was employed with the merging of two fragments bound to the active site, followed by structure-guided elaboration to design potent nanomolar inhibitors against Mab TrmD. Several of these compounds exhibit promising activity against mycobacterial species, including Mycobacterium tuberculosis and Mycobacterium leprae in addition to Mab, supporting the use of TrmD as a target for the development of antimycobacterial compounds.

Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers

A series of quinazoline derivatives with benzylidene hydrazine carboxamide were designed and synthesised as EGFR inhibitors. Most compounds exhibited exceptional anti-proliferative activity against A549, HepG2, MCF-7 and H1975 cells. Furthermore, six compounds demonstrated excellent inhibition activity against EGFRWT with the IC50 value both less than 2 nM. Among the six compounds, 44 exhibited the strongest activity (0.4 nM) and potently inhibited EGFRL858R/T790M (0.1 μM). Excitingly, the most potent compound 14 showed excellent enzyme inhibitory activity with 6.3 nM and 8.4 nM for both EGFRWT and EGFRT790M/L858R. The result of AO single staining and Annexin V/PI staining showed that the compound 14 and 44 could induce remarkable apoptosis of A549 cells. The compound 14 arrested the cell cycle at the S phase and compound 44 arrested the cell cycle at the G0 phase in A549 cells. These preliminary results demonstrate that compound 14 and 44 may be promising lead compound-targeting EGFR.

Improving cytotoxic properties of ferrocenes by incorporation of saturated N-heterocycles

A family of ferrocene derivatives of the general formula [Fe(η5-C5H4CH2(p-C6H4)CH2(N-het))2] bearing saturated six- and five-membered N-heterocycles (N-het) was prepar

METHODS OF PREPARING TOLL-LIKE RECEPTOR MODULATORS

The present invention provides methods of preparing 4-amino-2-biitoxy-8-(3- (pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one and related compounds.

Design, synthesis and AChE inhibitory activity of indanone and aurone derivatives

A new series of indanone and aurone derivatives have been synthesized and tested for in vitro AChE inhibitory activity by modified Ellman method. Most of them exhibit AChE inhibitory activities superior to rivastigmine. Further, the most potent compound 1g was selected to evaluate the effect on the acquisition and memory impairment by mice step-down passive avoidance test.

QUINOLIN-4-YLHYDRAZINE DERIVATIVES AS ANTIMALARIAL AGENT

Novel quinolyl and acridinylhydrazone compounds of formula (I), which present remarkable biological activity especially against the choloroquine-resistant Plasmodium falciparum strains, useful for the treatment and prevention of malaria infection are described herein.

Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains

A series of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones were synthesized and tested for their antimalarial properties. These compounds showed remarkable anti-plasmodial activity in vitro especially against chloroquine-resistant strains. Their pot

AMINE DERIVATIVE

The present invention provides a compound represented by the formula wherein Ar1 is a cyclic group optionally having substituent(s); R is a hydrogen atom, an optionally halogenated C1-6 alkyl, a phenyl optionally having substituent(s

PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS

The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds.